

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 2

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

1-19. (Canceled)

20. (Currently Amended) A method for evaluating the ability of an agent to inhibit binding of human ERAB polypeptide (SEQ. ID. NO: 2), or a fragment or polymorphism thereof, to amyloid-beta peptide which comprises:

- (a) incubating human ERAB polypeptide (SEQ. ID. NO: 2), or a fragment or polymorphism thereof, the agent and amyloid-beta peptide under suitable binding conditions;
- (b) determining the amount of amyloid-beta peptide bound to ~~human-ERAB~~ the polypeptide, fragment or polymorphism from the incubate of (a); and
- (c) comparing the amount of bound amyloid-beta peptide determined in step (b) to with an amount of amyloid-beta peptide bound to ~~human-ERAB~~ the polypeptide, fragment or polymorphism determined in the absence of the agent, wherein when the amount of amyloid-beta polypeptide bound to ~~human-ERAB~~ the polypeptide, fragment or polymorphism thereof is decreased in the

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 3

presence of said agent, the ability of the agent to inhibit binding of human ERAB polypeptide (SEQ. ID. NO: 2), or the fragment or polymorphism thereof, to amyloid-beta is determined.

21-26. (Canceled)

27. (Previously Presented) The method of claim 20, wherein the agent is a peptide.

28. (Previously Presented) The method of claim 20, wherein the agent is a peptidomimetic compound.

29. (Previously Presented) The method of claim 20, wherein the agent is a nucleic acid.

30. (Previously Presented) The method of claim 20, wherein the agent is a small molecule.